Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
New Approaches to Hematologic Malignancies Radiation Therapy
share announcement

New Approaches to Hematologic Malignancies Radiation Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 15 June 2024 | Viewed by 1978

Special Issue Editors

Prof. Dr. Peter Brossart

E-Mail Website
Guest Editor
Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany
Interests: multimodal immune; hematological oncology
Dr. Leonard Christopher Schmeel

E-Mail Website
Guest Editor
Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany
Interests: radiation-induced toxicities; radiation dermatitis

Special Issue Information

Dear Colleagues,

In this Special Issue, “New Approaches to Hematologic Malignancies Radiation Therapy”, we aim to present important recent developments in this field and discuss perspectives and possible future developments.

Substantial technological advances have facilitated the application increase radiation doses with high precision, resulting in both the improved sparing of healthy tissues and delivered dose to tumor sites. Increasing precision thus results in improved local tumor control and reduced side effects.

In hematological malignancies, the roles of imaging and biomarkers are steadily evolving and make radiation therapy more precise and personalized. Studies have demonstrated synergistic effects between radiation and immunotherapy. Cell-based adoptive immunotherapy strategies further enrich our therapeutic repertoire, and new interdisciplinary oncologic treatment concepts incorporating radiation therapy will arise.

In the light of these recent advances, the radiation therapy of hematological neoplasms is covered within this Special Issue. Reviews or original papers in the areas of (but are not limited to) tumor control, imaging modalities, multimodal immune- and cell-based therapies, radiation biology, personalized therapy, medical physics, and treatment toxicities are welcome.

Therefore, this issue will provide an overview of recent technological, biological, and clinical developments and advances in the radiation therapy of hematological malignancies.

We look forward to receiving your contributions.

Prof. Dr. Peter Brossart
Dr. Leonard Christopher Schmeel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hematological neoplasms
  • radiation therapy
  • tumor control
  • imaging modalities
  • multimodal immune
  • cell-based therapies
  • radiation biology
  • personalized therapy
  • medical physics
  • treatment toxicities

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1087 KiB  
Article
Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma—A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group
by Michael Oertel, Priska Hölscher, Dominik Hering, Christopher Kittel, Michael Fuchs, Uwe Haverkamp, Peter Borchmann and Hans Theodor Eich
Cancers 2024, 16(6), 1168; https://doi.org/10.3390/cancers16061168 - 16 Mar 2024
Viewed by 691
Abstract
Purpose: Hodgkin lymphoma is a hematologic malignancy with excellent outcomes even in advanced stages. Consequently, the importance of treatment-associated toxicity increases. However, the exact estimation of individualized rates is difficult due to different disease extents, treatment strategies and techniques. The following analysis aims [...] Read more.
Purpose: Hodgkin lymphoma is a hematologic malignancy with excellent outcomes even in advanced stages. Consequently, the importance of treatment-associated toxicity increases. However, the exact estimation of individualized rates is difficult due to different disease extents, treatment strategies and techniques. The following analysis aims at a pre-treatment estimation of relevant mediastinal toxicities. Methods: Normal tissue complication probability calculations were used to evaluate the toxicity rates for the heart, lungs and female breast of patients undergoing radiotherapy for early-stage Hodgkin lymphoma. Overall, 45 Patients of the HD16 and HD17 trials by the German Hodgkin study group were included and risks were calculated using the Lyman–Kutcher–Burman model. Results: The median values for pericarditis, pneumonitis and fibrosis of the left or right breast were 0.0%, 0.0%, 0.7% and 0.6% in the HD16 cohort, and 0.0%, 0.1%, 1.1% and 1.0% in the HD17 cohort, respectively. Correspondingly, none of the included patients displayed any of the evaluated toxicities during clinical follow-up. The use of higher doses (30 Gy) in the HD17 cohort led to an increase in toxicity compared to the HD16 cohort (20 Gy). No significant influence of the planning target volume size or the radiation technique could be found in this study. Conclusion: Both the clinically observed and calculated toxicity rates corroborate the overall low-risk profile of radiotherapy for Hodgkin lymphoma. Further treatment individualization will be attempted in the future. Full article
(This article belongs to the Special Issue New Approaches to Hematologic Malignancies Radiation Therapy)
►▼ Show Figures

Figure 1

12 pages, 3835 KiB  
Article
Optimized Conformal Total Body Irradiation with VMAT Using a Linear-Accelerator-Based Radiosurgery Treatment System in Comparison to the Golden Standard Helical TomoTherapy
by Mümtaz Köksal, Oğuzhan Özkan, Tobias Holderried, Annkristin Heine, Peter Brossart, Ahmed Gawish, Davide Scafa, Gustavo R. Sarria, Christina Leitzen, Leonard C. Schmeel and Thomas Müdder
Cancers 2023, 15(17), 4220; https://doi.org/10.3390/cancers15174220 - 23 Aug 2023
Viewed by 1085
Abstract
Modern irradiation techniques for optimized conformal TBI can be realized by Helical Tomotherapy (HT) or Volumetric Modulated Arc Therapy (VMAT), depending on the availability of suitable specialized equipment. In this dosimetric planning study, we compared both modalities and addressed the question of whether [...] Read more.
Modern irradiation techniques for optimized conformal TBI can be realized by Helical Tomotherapy (HT) or Volumetric Modulated Arc Therapy (VMAT), depending on the availability of suitable specialized equipment. In this dosimetric planning study, we compared both modalities and addressed the question of whether VMAT with small field sizes is also suitable as a backup in case of HT equipment malfunctions. For this purpose, we retrospectively used planning computed tomography (CT) data from 10 patients treated with HT with a total dose of 8 Gy (n = 5) or 12 Gy (n = 5) for treatment planning for VMAT with a small field size (36 × 22 cm). The target volume coverage, dose homogeneity at target volume, and dose reduction in organs at risk (OAR) (lungs, kidneys, lenses) were analyzed and compared. One patient was irradiated with both modalities due to a device failure of the HT equipment during the study, which facilitated a comparison in a real clinical setting. The findings indicate that in addition to a higher mean dose to the lenses in the 12 Gy group for VMAT and a better dose homogeneity in the target volume for HT, comparably good and adequate target dose coverage and dose reduction in the other OAR could be achieved for both modalities, with significantly longer treatment times for VMAT. In conclusion, after appropriate optimization of the treatment times, VMAT using linear accelerator radiosurgery technology can be used both as a backup in addition to HT and in clinical routines to perform optimized conformal TBI. Full article
(This article belongs to the Special Issue New Approaches to Hematologic Malignancies Radiation Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop